Nivolumab plus ipilimumab plus chemo vs pembrolizumab plus chemo in PD-L1 negative metastatic NSCLC patients: comparative effectiveness using the target trial emulation framework.

First published 30/10/2026

Last updated 30/10/2026

EU PAS number:

EUPAS1000001143

Study

Planned

Download as PDF

Documents

Study protocol

Initial protocol

EUPAS1000001143_study_protocol.pdf

English (1.15 MB - PDF) View document

Study results

No information provided.

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Nivolumab plus ipilimumab plus chemo vs pembrolizumab plus chemo in PD-L1 negative metastatic NSCLC patients: comparative effectiveness using the target trial emulation framework.

Secondary tabs

Share this page